IND for ATA-100, a Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), cleared to proceed by FDA

Atamyo Therapeutics announced that the U.S. Food & Drug Administration has cleared its Investigational New Drug application for ATA-100 to proceed in a Phase 1b/2b clinical trial.